Drug Profile


Alternative Names: 1 alpha-hydroxyergocalciferol; 1-alpha-D2; 1-alpha-Hydroxyvitamin D2; GZ-427397; Hectorol; TSA 870

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Wisconsin at Milwaukee
  • Developer Genzyme Corporation; Sanofi Genzyme
  • Class Calcium regulators; Ergocalciferols; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperparathyroidism
  • Discontinued Breast cancer; Colorectal cancer; Plaque psoriasis; Postmenopausal osteoporosis; Prostate cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Dec 2016 Phase-III clinical trials in Hyperparathyroidism (In children, In adolescents) in USA (PO) (NCT02859896)
  • 04 Aug 2016 Sanofi plans a phase III trial for Secondary hyperparathyroidism (In children, In adolescents) in USA (NCT02859896)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top